# Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

> **NCT04572308** · PHASE1 · COMPLETED · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- T-cell Acute Lymphoblastic Leukemia/Lymphoma

## Interventions

- **BIOLOGICAL:** CD7 CAR-T

## Key facts

- **NCT ID:** NCT04572308
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-05-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04572308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04572308, "Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04572308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*